Related references
Note: Only part of the references are listed.Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
Rune V. Overgaard et al.
DIABETES THERAPY (2019)
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Ippei Ikushima et al.
ADVANCES IN THERAPY (2018)
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
Kohei Kaku et al.
DIABETES OBESITY & METABOLISM (2018)
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
Lene Jensen et al.
DIABETES OBESITY & METABOLISM (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type2 diabetes mellitus: A post-hoc analysis of a phase3 randomized clinical trial
Shizuka Kaneko et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Kristin Cecilie Carlsson Petri et al.
DIABETES THERAPY (2018)
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Kristin Cecilie Carlsson Petri et al.
DIABETES THERAPY (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication
Cheng Hu et al.
DIABETES (2018)
Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Limin Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Thomas C. Marbury et al.
CLINICAL PHARMACOKINETICS (2017)
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Helene Hausner et al.
CLINICAL PHARMACOKINETICS (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences
Michael Horowitz et al.
DIABETES OBESITY & METABOLISM (2017)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
Christoph Kapitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study
Pedro de Pablos-Velasco et al.
CLINICAL ENDOCRINOLOGY (2014)
Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients
Linong Ji et al.
AMERICAN JOURNAL OF MEDICINE (2013)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
Sarah Stark Casagrande et al.
DIABETES CARE (2013)
Impact of Waist Circumference and Body Mass Index on Risk of Cardiometabolic Disorder and Cardiovascular Disease in Chinese Adults: A National Diabetes and Metabolic Disorders Survey
Xuhong Hou et al.
PLOS ONE (2013)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Share Paper
